Under the agreement, BioVision will analyze biological samples provided by Abbott to discover lung cancer tumor biomarkers. In return, the company will receive research fees and might obtain milestone and royalty payments, depending on the success of the research.
BioVision specializes in the identification of disease-relevant peptides and proteins.